LGVN Longeveron

Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024

Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024

MIAMI, Dec. 02, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the Emerging Growth Virtual Conference taking place December 4-5, 2024.

Details for the Company’s presentation:

Date:December 5, 2024
Time:12:00 – 12:30 p.m. ET
  

The webcast for this conference presentation may be accessed at the “” section of the Company’s website. A replay of the webcast will be available on the Longeveron website for 180 days following the conference.

Questions may be submitted in advance to or asked during the event.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-BTM development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit or follow Longeveron on , , and .

Investor and Media Contact:

Derek Cole

Investor Relations Advisory Solutions 



EN
02/12/2024

Underlying

LGVNLongeveron

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Longeveron

 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

Longeveron® Appoints Stephen H. Willard as Chief Executive Officer Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant fundraises and strategic collaborationsCorporate focus on delivering top-line results from the pivotal Phase 2b clinical trial in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the third quarter of 2026 Than Powell stepped down as interim CEO; will remain with the Company to support the leadership transition and continue...

February 13, 2026 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance A...

Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program The Mikaela Naylon Give Kids a Chance Act reauthorizes the Pediatric Priority Review Voucher (PPRV) Program and extends eligibility for medicines achieving U.S. FDA approval before September 2029The Pediatric Priority Review Voucher program encourages the development of treatments for rare pediatric diseasesU.S. FDA has awarded Longeveron’s laromestrocel Hypoplastic Left Heart Syndrome (HLHS) program Rare Pediatric Disease designation, Orphan...

February 5, 2026 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron® Granted Japan Patent for Potency Assay Methods for Assessi...

Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs) The patent relates to potency assay methods for assessing human mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, peripheral blood, a lung, a heart, amniotic fluid, inner organs, an amniotic membrane, an umbilical cord or a placenta or differentiated from induced pluripotent stem cells (IPSCs)Patent issuance contributes to Longeveron’s growing international patent portfolio protecting its clinical programs and productsLaromestrocel, Longeveron’s proprietary mese...

January 29, 2026 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout f...

Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS) ELPIS II top-line trial results are anticipated in the third quarter of 2026Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated if ELPIS II results are positiveU.S. FDA has awarded laromestrocel HLHS program Rare Pediatric Disease designation, Orphan Drug designation, and Fast Track designationLaromestrocel HLHS program has the potential to address an unm...

January 26, 2026 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron, Selected as a StartUp Health Alzheimer’s Disease Moonshot ...

Longeveron, Selected as a StartUp Health Alzheimer’s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026 Mission-aligned community focused on accelerating breakthroughs in Alzheimer’s disease, Parkinson’s disease and related conditionsSupported by Health Moonshot Champions, including the Alzheimer’s Drug Discovery Foundation (ADDF) and Gates VenturesApollo House, the Founders & Funders Networking Summit, to bring together founders, funders and industry leaders addressing Health Moonshots worldwideLongeveron will also be hosting meetings ...

December 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch